Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Angry??? Not in the least. I see things my way, you go and play with your charts. All's good here the way I read it. Like I said, charts and analysis of charts are wrong more that right. All they do is show current price, they are a tool to try to predict the path the price is going, very unpredictable. I stick with company updates, news, prs, that's what moves charts. Glty
Don't mean squat. Charts go up and down, news and company is what pushes charts up and down. MMs manipulate, flippers flip, news comes, boom. Charts shift and tread in all directions. Patients is need in pinky land, the wait can drive you nuts, but when the "strong hands" hang, and news breaks that makes it all worth it, you make you moves on charts going up and down when you know the company is solid, and you sell, you have no one to blame but your self. I will go with DD company news, Not charts.
Its gonna be a greenie Winnie day here in NOUV land. Its comming, maybe today.
Prove their dumping shares, you can't. Its flippers and M&M's only trying to get cheapies and shorts covering. Duh...
The beat down is done, going up from here.
Trying to hold it down before news...lol ankles, nice buying opportunity though..get now if your getting them. Boom time comming. Imo
I think, if you look at each ticker and what ticker is related to what ticker(partner). Such as PURA, Kali, NOUV, They are partners under USCH.
Now if some company brought USCH as a whole, that would involve PURA, Kali and NOUV.
If just one ticker has news about their product, such as PURA EverX, which the CBD content being upped to 25% from 10%, would be made out to benefit PURA, even know Kaly extracted Nouv's hemp to up the CBD. They would mention Kaly and NOUV in the marketing aspect because its pura product, even know Kaly is licenced through PURA for exstration already, and NOUV supplied the hemp. Everyone benefits, but it doesn't show for Kaly and NOUV even know its profit for all. Just my way of looking at it, too bad peeps all Don't see it that way. I think once financials come out for NOUV you will see what I'm talking about...lol
I like this article better. Close to home. PURA, Kaly and NOUV home base is in Texas. Were going to be huge very, very soon.
Sen. Perry files bill to legalize hemp growing in Texas
By Jayme Lozano A-J Media
Posted Feb 28, 2019 at 11:21 AM
Updated Feb 28, 2019 at 11:21 AM
?Director of Global Production, Brian Furnish, inspects hemp plants that have been hung to dry at Ananda Hemp in Cynthiana, Ky., Thursday, Jan 24, 2019. (AP Photo/Bryan Woolston)?
?Perry?
State Sen. Charles Perry filed a bill Wednesday that could open the door for farmers in Texas to legally grow hemp.
The Lubbock Republican's filing of SB 1240 comes after the 2018 U.S. Farm Bill gave a pathway for states to authorize farmers to grow industrial hemp, a crop that cannot exceed a THC level of 0.3 percent and does not have the ability to create the "high" of marijuana.
The bill is a change from the 2014 version that allowed farmers in some states to grow the crop as part of pilot programs with universities or state departments. With the change in the law, there is also the provision that each state must present their own plan to the federal government for approval.
"Hemp products are bought and sold every day in Texas in stores like H-E-B and United," said Perry. "However, farmers in Texas do not get to profit off this production like farmers in 41 other states. Why should our hardworking farmers not have the same opportunity?"
Perry added that the bill would require a farmer to go through a background check, obtain a license, and have a third party test their crop to ensure THC levels stay "very low." Perry warned that anyone who abuses the system could have their crop destroyed and lose their license.
The Texas Farm Bureau also offered support for the bill, saying hemp production is a viable crop option in Texas.
"We urge the legislature to remove barriers to its production here," said Russell Boening, TFB President. "It is a drought tolerant crop with many uses that can be grown anywhere in our state."
Boening added, "Hemp should be another crop option for Texas farmers who are struggling with low commodity prices."
© Copyright 2006-2019 GateHouse Media, LLC. All rights reserved • GateHouse News
Original content available for non-commercial use under a Creative Commons license, except where noted.
Lubbock Avalanche-Journal ~ 710 Avenue J, Lubbock, TX 79401 ~ Privacy Policy ~ Terms Of Service
The ball is rolling. Just a matter of time, and by the looks of it, not a very long time at this hat. Were good, we huge, were hemp cultivators, NOUV. Great news, thank you...
FDA has to have their cut, its all good everything will explode as soon as they say go, which I have no fought they will very soon. Lots of money to be made off CBD, matter of time.
And PURA would be just water..lol package deal imo, or nothing. After all we are partners under USCH. PURA, Kaly and NOUV.
Moving forward is Bullshit? Ok, we will go backwards, now that would be Bullshit.
What's PURA without hemp and extraction? Water? Package deal, we are partners
Hey tell me something. Marketing, who pays for that? Is it any different than promoting...Humm think you better compare, don't think there's a difference in them. Their selling their product AH, plus giving input in the direction the company is heading. Oh why would I think you would know this, its too much for you and PR to comprehend, or is there an agenda being played here between you two? Give the nonscence a break would yas.
Wake up people, Lets get the show started, get a jump on news and we go much higher.
Off to the races...lol
Its getting better all the time, better, better. Beatles
Spun off company? Who might that be? Wouldn't happen to be NOUV now would it? Huge....
Quote from article...
(As of October 2018, the Company was set to spin off its cannabis cultivation segment to focus its efforts exclusively on its high-growth core CBD-infused beverage business.)
?
Date: February 28, 2019
PURA - Puration Speculative Buy Confirmed With $0.25 Target PPS And $0.35 PPS Potential Upside In Updated Analyst Report
Symbol: PURA
February 28, 2019 -- InvestorsHub NewsWire -- via GoldmanResearch.com -- Puration, Inc. (USOTC: PURA) today announced that Goldman Small Cap Research issued a research update on the Company. The report includes a 'speculative-buy' rating with a target price-per-share of $0.25, with noted potential upside to the $0.35 mark. The update reviews recent events and provides an analysis of Puration’s recent new initiatives. To view the update report, along with disclosures and disclaimers, visit http://www.GoldmanResearch.com.
Puration Goldman Small Cap Research Update Highlights
Puration, Inc. is a leading Texas-based, CBD-infused beverage provider. The Company’s flagship product, EVERx, which was introduced in 2017, targets the sports nutrition market. Puration plans to introduce new beverages as well as grow it product portfolio organically as well as through targeted acquisitions. As of October 2018, the Company was set to spin off its cannabis cultivation segment to focus its efforts exclusively on its high-growth core CBD-infused beverage business.
According to a report by the Brightfield Group, the hemp-derived CBD market is forecast to reach $22 billion in 2022. Given that the market remains fragmented, fast-growing PURA is well positioned to capture market share very quickly.
In the Opportunity Research update, analyst Rob Goldman discusses the Company’s strong initiatives, and exciting upcoming opportunities that lie ahead.
Goldman noted, “In a business segment that features pretenders and also-rans, PURA is already a clear winner and emerging leader. Since our November 2018 update, PURA has signed a major contract, introduced new formulations/packaging, added global distribution and is enjoying substantial repeat orders. As a result, our FY19 $3M in revenue estimate could be low. Given the M&A, investment and business exploration activity by major consumer products companies, we expect PURA to return to its 52-week high of $0.25 with potential upside to the $0.35 mark and be considered an M&A candidate.”
“PURA has bagged a $1.5M custom CBD extracts order with Generex Biotechnology, gone global with a new European distributor and is a major sponsor of key events such as the 2019 The Arnold Sports Festival, which will be attended by 200,000 visitors watching 22,000 athletes compete.”
“There is substantial interest in hemp-derived CBD-infused products, as evidenced by the flurry of M&A, investment activity and talk by major beverage companies such as Constellation, Brands, Diageo, Tilray, Coca-Cola, Starbucks, etc. Once critical mass of sales is achieved, given its broad popularity, PURA could emerge as an M&A target,” concluded Goldman.
About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.
Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published sponsored company research report on Puration, Inc. which carries a rating and a price target. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from Puration, Inc. (“the Company”) authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov. ;
Separate from the factual content of our report about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. To download this research report or any of our research, view our disclosures and disclaimers, or for more information, visit www.goldmanresearch.com. Since 2018, Goldman Small Cap Research has been compensated $7000 by the Company for research and distribution services. GSCR was not compensated for the production and distribution of this update.
About Puration, Inc. (OTC - PURA) Puration, Inc. is a leading Texas-based, CBD-infused beverage provider. The Company’s flagship product, EVERx, which was introduced in 2017, targets the sports nutrition market. Puration plans to introduce new beverages as well as grow it product portfolio organically as well as through targeted acquisitions. As of October 2018, the Company was set to spin off its cannabis cultivation segment to focus its efforts exclusively on its high-growth core CBD-infused beverage business.
For more information, please visit: www.PurationInc.com
Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
rob@goldmanresearch.com
View source version on Investorshub.com: https://ih.advfn.com/p.php?pid=nmona&article=79369531
?
InvestorsHub has been paid by a third party to disseminate this news.
To unsubscribe from this news bulletin or edit your mailing list settings click here.
Registered address: PO Box 780, Harrisonville, MO 64701-0780
?
Date: February 28, 2019
PURA - Puration Speculative Buy Confirmed With $0.25 Target PPS And $0.35 PPS Potential Upside In Updated Analyst Report
Symbol: PURA
February 28, 2019 -- InvestorsHub NewsWire -- via GoldmanResearch.com -- Puration, Inc. (USOTC: PURA) today announced that Goldman Small Cap Research issued a research update on the Company. The report includes a 'speculative-buy' rating with a target price-per-share of $0.25, with noted potential upside to the $0.35 mark. The update reviews recent events and provides an analysis of Puration’s recent new initiatives. To view the update report, along with disclosures and disclaimers, visit http://www.GoldmanResearch.com.
Puration Goldman Small Cap Research Update Highlights
Puration, Inc. is a leading Texas-based, CBD-infused beverage provider. The Company’s flagship product, EVERx, which was introduced in 2017, targets the sports nutrition market. Puration plans to introduce new beverages as well as grow it product portfolio organically as well as through targeted acquisitions. As of October 2018, the Company was set to spin off its cannabis cultivation segment to focus its efforts exclusively on its high-growth core CBD-infused beverage business.
According to a report by the Brightfield Group, the hemp-derived CBD market is forecast to reach $22 billion in 2022. Given that the market remains fragmented, fast-growing PURA is well positioned to capture market share very quickly.
In the Opportunity Research update, analyst Rob Goldman discusses the Company’s strong initiatives, and exciting upcoming opportunities that lie ahead.
Goldman noted, “In a business segment that features pretenders and also-rans, PURA is already a clear winner and emerging leader. Since our November 2018 update, PURA has signed a major contract, introduced new formulations/packaging, added global distribution and is enjoying substantial repeat orders. As a result, our FY19 $3M in revenue estimate could be low. Given the M&A, investment and business exploration activity by major consumer products companies, we expect PURA to return to its 52-week high of $0.25 with potential upside to the $0.35 mark and be considered an M&A candidate.”
“PURA has bagged a $1.5M custom CBD extracts order with Generex Biotechnology, gone global with a new European distributor and is a major sponsor of key events such as the 2019 The Arnold Sports Festival, which will be attended by 200,000 visitors watching 22,000 athletes compete.”
“There is substantial interest in hemp-derived CBD-infused products, as evidenced by the flurry of M&A, investment activity and talk by major beverage companies such as Constellation, Brands, Diageo, Tilray, Coca-Cola, Starbucks, etc. Once critical mass of sales is achieved, given its broad popularity, PURA could emerge as an M&A target,” concluded Goldman.
About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.
Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published sponsored company research report on Puration, Inc. which carries a rating and a price target. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from Puration, Inc. (“the Company”) authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov. ;
Separate from the factual content of our report about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. To download this research report or any of our research, view our disclosures and disclaimers, or for more information, visit www.goldmanresearch.com. Since 2018, Goldman Small Cap Research has been compensated $7000 by the Company for research and distribution services. GSCR was not compensated for the production and distribution of this update.
About Puration, Inc. (OTC - PURA) Puration, Inc. is a leading Texas-based, CBD-infused beverage provider. The Company’s flagship product, EVERx, which was introduced in 2017, targets the sports nutrition market. Puration plans to introduce new beverages as well as grow it product portfolio organically as well as through targeted acquisitions. As of October 2018, the Company was set to spin off its cannabis cultivation segment to focus its efforts exclusively on its high-growth core CBD-infused beverage business.
For more information, please visit: www.PurationInc.com
Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
rob@goldmanresearch.com
View source version on Investorshub.com: https://ih.advfn.com/p.php?pid=nmona&article=79369531
?
InvestorsHub has been paid by a third party to disseminate this news.
To unsubscribe from this news bulletin or edit your mailing list settings click here.
Registered address: PO Box 780, Harrisonville, MO 64701-0780
?
Date: February 28, 2019
PURA - Puration Speculative Buy Confirmed With $0.25 Target PPS And $0.35 PPS Potential Upside In Updated Analyst Report
Symbol: PURA
February 28, 2019 -- InvestorsHub NewsWire -- via GoldmanResearch.com -- Puration, Inc. (USOTC: PURA) today announced that Goldman Small Cap Research issued a research update on the Company. The report includes a 'speculative-buy' rating with a target price-per-share of $0.25, with noted potential upside to the $0.35 mark. The update reviews recent events and provides an analysis of Puration’s recent new initiatives. To view the update report, along with disclosures and disclaimers, visit http://www.GoldmanResearch.com.
Puration Goldman Small Cap Research Update Highlights
Puration, Inc. is a leading Texas-based, CBD-infused beverage provider. The Company’s flagship product, EVERx, which was introduced in 2017, targets the sports nutrition market. Puration plans to introduce new beverages as well as grow it product portfolio organically as well as through targeted acquisitions. As of October 2018, the Company was set to spin off its cannabis cultivation segment to focus its efforts exclusively on its high-growth core CBD-infused beverage business.
According to a report by the Brightfield Group, the hemp-derived CBD market is forecast to reach $22 billion in 2022. Given that the market remains fragmented, fast-growing PURA is well positioned to capture market share very quickly.
In the Opportunity Research update, analyst Rob Goldman discusses the Company’s strong initiatives, and exciting upcoming opportunities that lie ahead.
Goldman noted, “In a business segment that features pretenders and also-rans, PURA is already a clear winner and emerging leader. Since our November 2018 update, PURA has signed a major contract, introduced new formulations/packaging, added global distribution and is enjoying substantial repeat orders. As a result, our FY19 $3M in revenue estimate could be low. Given the M&A, investment and business exploration activity by major consumer products companies, we expect PURA to return to its 52-week high of $0.25 with potential upside to the $0.35 mark and be considered an M&A candidate.”
“PURA has bagged a $1.5M custom CBD extracts order with Generex Biotechnology, gone global with a new European distributor and is a major sponsor of key events such as the 2019 The Arnold Sports Festival, which will be attended by 200,000 visitors watching 22,000 athletes compete.”
“There is substantial interest in hemp-derived CBD-infused products, as evidenced by the flurry of M&A, investment activity and talk by major beverage companies such as Constellation, Brands, Diageo, Tilray, Coca-Cola, Starbucks, etc. Once critical mass of sales is achieved, given its broad popularity, PURA could emerge as an M&A target,” concluded Goldman.
About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.
Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published sponsored company research report on Puration, Inc. which carries a rating and a price target. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from Puration, Inc. (“the Company”) authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov. ;
Separate from the factual content of our report about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. To download this research report or any of our research, view our disclosures and disclaimers, or for more information, visit www.goldmanresearch.com. Since 2018, Goldman Small Cap Research has been compensated $7000 by the Company for research and distribution services. GSCR was not compensated for the production and distribution of this update.
About Puration, Inc. (OTC - PURA) Puration, Inc. is a leading Texas-based, CBD-infused beverage provider. The Company’s flagship product, EVERx, which was introduced in 2017, targets the sports nutrition market. Puration plans to introduce new beverages as well as grow it product portfolio organically as well as through targeted acquisitions. As of October 2018, the Company was set to spin off its cannabis cultivation segment to focus its efforts exclusively on its high-growth core CBD-infused beverage business.
For more information, please visit: www.PurationInc.com
Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
rob@goldmanresearch.com
View source version on Investorshub.com: https://ih.advfn.com/p.php?pid=nmona&article=79369531
?
InvestorsHub has been paid by a third party to disseminate this news.
To unsubscribe from this news bulletin or edit your mailing list settings click here.
Registered address: PO Box 780, Harrisonville, MO 64701-0780
Nice feeling, could be done very easy. Considerate on the ask peeps, she will go on air.
Push, push baby.
Going up, better catch it now, no turning back. Hit it boys and girls.
Smack the puss out of the ask today, time to get this moving along with PURA and Kaly. We are as one.
PURA just shot past 14s, going big there, it will here also.
If buys hitting now.
It will head up, somethings in the grapevine for here and PURA. Then NOUV will kick in. News comming, its hump day.
Yeah, sure looks like it...Lmfao
NOT, heading up big time today, hold tight people.
Next step up will come today.
Something big going on, insiders are in the know.
PURA opening above 12 today... Nice
6s open, on its way up to 7s maybe 8s today..
Nobodies blindsided. Duhhh
You know somethings in the grapevine when PURA and Kaly are both moving up. News comming????
Lol, yeah right, Go away
Damm, MM manipulation here is brutal. When this goes, she's gonna fly. No holding back by MMs.
PURA already has its own THC beer. Savor. There's a Lot going on in the background here I think.
Your right, have to agree, but I know if Kaly and PURA have good news were involved. In holding for the long haul. Something huge will come sooner or later...
PURA sky rocketing